MissionYale Cancer Center’s mission is to deliver the highest quality patient-centered care, achieve breakthrough discoveries, and train future leaders in cancer science and medicine. Yale Cancer Center members are the cornerstone of that commitment.
Cancer Center Support Grant (CCSG)
The NCI has designated Yale Cancer Center (YCC) among its only 47 Comprehensive Cancer Centers in the country via a rigorous grant application and review process. YCC has proven to be a global leader in cancer care, research and education with $102.6M in total funding which includes $79.5M peer-reviewed funding and $30.2M NCI funding. The National Cancer Institute (NCI) may award a CCSG to any non-profit institution within the United States with a peer-reviewed cancer research base of at least 4 million dollars. The objective of a CCSG is not to directly support research projects, but to enhance, strengthen, and increase the institution’s ongoing cancer research with the ultimate goal of reducing cancer incidence, mortality, and morbidity. The CCSG provides the resources and infrastructure to facilitate the coordination of YCC’s seven interdisciplinary research programs from basic laboratory research to clinical investigations including therapeutic clinical trials to population sciences that look into the question of how to reduce the risk, incidence, and death from cancer, as well as enhance the quality of life for cancer survivors.
Organized into seven thematically-aligned Research Programs, our roster consists of Yale faculty members and researchers who have undergone a formal application process and have been selected for their major cancer related efforts based on their track record for cancer research and publications. YCC members pledge to collaborate in order to advance the scientific goals of the Cancer Center in accordance with the guidelines for the Cancer Center Support Grant (CCSG) from the National Cancer Institute.
Valuable Contributions to Cancer Research, Treatment, Prevention, and Education
Members of our seven Research Programs have produced game-changing research and treatment innovations that have had international impact on cancer knowledge. Our nearly 200 peer-reviewed grants* from the NCI, NIH, American Cancer Society, and other institutions means that our faculty are among the top in the country in cancer discoveries and advances. Following are just a few of those advances:
- Exercise Improves Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors (Melinda Irwin, PhD, MPH, Cancer Prevention and Control)
- Long-term use of aspirin may reduce risk for pancreatic cancer (Harvey A. Risch, MD, PhD, Cancer Prevention and Control)
- Stand Up to Cancer MRA Dream Team: Personalized Medicine for Patients with BRAF Wild-Type Cancer (Patricia M. LoRusso, DO, Developmental Therapeutics)
- The New Era of Immune Checkpoint Inhibitors (Lieping Chen, MD, PhD, Cancer Immunology)
- Researchers Try to Make Sure Herpes Does Not Find a Home (Akiko Iwasaki, PhD, Molecular Virology)
- Potential Treatment Combinations for Melanoma Identified Through Novel Screening Approach (David F. Stern, PhD, Signal Transduction; Marcus W. Bosenberg, MD, PhD, Cancer Genetics & Genomics)
- New Guideline on Lumpectomy Margins Should Reduce Re-excision (Meena Moran, MD, Radiobiology and Radiotherapy)
- Education and Training: Schwartz Rounds, Grand Rounds, Fellowship and Residency Opportunities, Yale Cancer Center “Answers” on WNPR
*Grants data current as of September 1, 2015.
Current Yale Cancer Center Membership (as of November, 2016)